Abstract
The potential role of serum RBP4 and THBS2 as biomarker in colorectal cancer (CRC) diagnosis has never been studied. We investigated in large sample using quantitative ELISA method to explore whether serum RBP4 and THBS2 can act as biomarkers for CRC diagnosis. The concentration of RBP4 and THBS2 was measured in 402 CRC patients’ serum samples and 218 normal controls’ serum samples. The results showed that the average RBP4 and THBS2 concentrations in normal controls were significantly higher than in CRC patients (36.5±11.4μg/mL vs 21.8±8.7μg/mL and 20.5±6.1ng/mL vs 14.5±7.3ng/mL, respectively), both p<0.001. RBP4 distinguished CRC patients from normal individuals with the area under the receiver operating characteristic curve (AUC) performing at 0.852, with sensitivity of 74.9% and specificity of 81.7%. While THBS2 distinguished CRC patients performing AUC at 0.794, with sensitivity of 64.9% and specificity of 87.1%. The ability of RBP4 and THBS2 serum concentration distinguishing CRC from normal controls showed better than that of serum CEA (AUC=0.818) or CA19-9 (AUC=0.650) concentration. This is the first study to report RBP4 and THBS2 as diagnosis serum biomarkers for CRC, which might be a good supplement for CEA or CA19-9 for clinical diagnosis.
Highlights
Colorectal cancer (CRC) is the third most common cancer and the fourth leading cause of deaths
We investigated in large sample using quantitative ELISA method to explore whether serum RBP4 and THBS2 can act as biomarkers for colorectal cancer (CRC) diagnosis
The serum RBP4 and THBS2 concentrations were graded according to the 7th edition of the International Union against Cancer (UICC) tumor node metastasis (TNM)
Summary
Colorectal cancer (CRC) is the third most common cancer and the fourth leading cause of deaths. It is responsible for over 500,000 deaths annually worldwide [1]. The overall five year survival rate of patients with CRC is 66%. More than 63% CRC patients are diagnosed at an advanced stage, and the survival rate of them is only about 10%-30% [2]. CEA and CA19-9 are currently most common used serum tumor markers for diagnosis of CRC. In CRC patients, CEA and CA19-9 showed various degrees of sensitivity depending on the stage of disease. Since most stage II CRC are potentially curable, the most beneficial diagnostic markers for screening would be able to detect the disease at stage II or even more earlier. Finding new serum markers for diagnosis of CRC is necessary
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
